Hansoh rises on positive clinical trial results for plaque psoriasis drug

Hansoh Pharmaceutical

21/09/2026 04:39

** Shares of Hansoh Pharmaceutical Group 3692.HK rise 4.3% to HK$35.76, their highest level since September 9
** Stock on course for biggest one-day pct gain since September 14
** Pharmaceutical producer says phase III clinical trial of HS-10374 in treatment of moderate-to-severe plaque psoriasis has met co-primary endpoints and multiple secondary endpoints and has demonstrated a favourable safety and tolerability profile
** The group will initiate communications with relevant regulatory authority to advance preparations for new drug application in China in near term - Hansoh  
** YTD, stock down 1.6%, while Hang Seng Biotech Index .HSBIO up 16%

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))